TRICYCLIC BENZIMIDAZOLE, ITS PRODUCTION AND BLOOD FLOW DISORDER THERAPEUTIC AGENT CONTAINING SAID COMPOUND

Novel tricyclic benzimidazoles of the formula I in which R1 represents an optionally substituted phenyl ring, a naphthyl radical or a saturated or unsaturated heterocyclic 5-membered ring having 1-4 heteroatoms or a heterocyclic 6-membered ring having 1-5 heteroatoms, where the heteroatoms can be identical or different and denote oxygen, sulphur or nitrogen and, if desired, can carry an oxygen atom on one or more nitrogen atoms, and the 5- or 6-membered rings can optionally be substituted by one or more alkyl, alkoxy, alkylmercapto, hydroxyl, nitro, amino, halo or cyano groups or can be condensed with a phenyl ring to give a bicycle, or in the case in which X represents a bond, R1 in addition to the abovementioned groups also denotes a hydrogen atom, an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, haloalkyl, alkoxyalkyl, carboxyalkyl, alkoxycarbonylalkyl, aminoalkyl, hydroxyalkyl, hydroxyl, mercapto, amino, alkylmercapto, alkylcarbonylamino, formylamino, alkylsulphonylamino, formylaminoalkyl, alkoxycarbonylaminoalkyl, alkylsulphonylaminoalkyl, alkoxycarbonylamino, trifluoromethyl or alkylcarbonylaminoalkyl group, X denotes a bond, an alkylene group, the vinylene group, the imino group -NH- or the amide group -CONH-, and A, B, C and D independently of one another denote carbon and nitrogen atoms which can be substituted by hydrogen, alkyl groups or cycloalkyl groups, where the carbon atoms can also carry hydroxyl or oxo groups or can be constituents of a 3-7-membered spirocycle, where the 6-membered ring containing A, B, C and D can be saturated, partially unsaturated or unsaturated, their tautomers and their physiologically tolerable salts of inorganic or organic acids, for the treatment of circulatory disorders, where they inhibit platelet and erythrocyte aggregation.